(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc.: What: Presentation of Phase 2 Data on ATX-101, a First-in-Class, Novel, Injectable Drug For The Reduction of Localized Fat and New Data on Pharmacokinetics, Histology and MOA.
(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc.: What: Presentation of Phase 2 Data on ATX-101, a First-in-Class, Novel, Injectable Drug For The Reduction of Localized Fat and New Data on Pharmacokinetics, Histology and MOA.
